Kymera Therapeutics Inc
$ 87.71
1.82%
17 Apr - close price
- Market Cap 7,032,676,000 USD
- Current Price $ 87.71
- High / Low $ 88.45 / 87.06
- Stock P/E N/A
- Book Value 19.42
- EPS -3.69
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.26 %
- 52 Week High 103.00
- 52 Week Low 25.50
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$119.14
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-29 | 2025-08-11 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.97 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 | -0.7 |
| Estimated EPS | -0.79 | -0.8613 | -0.83 | -0.73 | -0.7882 | -0.84 | -0.68 | -0.73 | -0.4 | -0.64 | -0.71 | -0.68 |
| Surprise | -0.18 | -0.0787 | -0.12 | -0.09 | -0.1018 | 0.02 | 0.1 | 0.11 | 0.15 | -0.26 | 0.04 | -0.02 |
| Surprise Percentage | -22.7848% | -9.1374% | -14.4578% | -12.3288% | -12.9155% | 2.381% | 14.7059% | 15.0685% | 37.5% | -40.625% | 5.6338% | -2.9412% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.89 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-04-17 07:09:21
Kymera Therapeutics director Bruce Booth recently sold 9,494 shares of common stock for approximately $854,538, following a significant surge in the company's stock price over the past year. Concurrently, Booth exercised options to acquire 6,359 shares. This comes as Kymera Therapeutics receives Fast Track designation for KT-621 and Gilead Sciences licenses KT-200, highlighting key advancements in their drug pipeline.
2026-04-17 07:09:21
Kymera Therapeutics' COO, Jeremy G. Chadwick, sold 6,551 shares of common stock for approximately $589,598 on April 14 and 15, 2026, amid a 244% surge in the stock over the past year. Concurrently, Chadwick exercised options to acquire the same number of shares for a total of $225,436. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, with the stock currently trading below the sale price and deemed overvalued by InvestingPro.
2026-04-17 07:09:21
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick sold 5,251 shares of company stock for $472,590 on April 14th, reducing his stake by 7.9%. This insider selling occurred shortly after the company missed EPS and revenue estimates, despite large institutions increasing their holdings and analysts generally rating KYMR as a Buy with an average target price of $118.90.
2026-04-16 23:40:15
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth sold 4,159 shares of the company's stock on April 14th at an average price of $89.97, reducing his position by 50%. This sale, along with other recent transactions, was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the stock falling 3.2% after a Q1 earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $118.90.
2026-04-16 23:39:41
Kymera Therapeutics (NASDAQ:KYMR) insider Noah Goodman sold 1,347 shares worth $121,230 on April 14th, further reducing his stake after earlier sales in the month. This insider selling comes despite the company reporting an earnings miss with significantly lower revenue than expected. Nevertheless, analysts maintain a "Moderate Buy" consensus rating with an average target price of $118.90, suggesting continued bullish sentiment despite recent financial setbacks and insider activity.
2026-04-16 22:39:41
Kymera Therapeutics director Bruce Booth sold 9,494 shares of common stock for approximately $854,538 in mid-April 2026, following a significant surge in the company's stock price over the past year. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. Booth also exercised options to acquire 6,359 shares.
